{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T16:30:53Z","timestamp":1780677053978,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T00:00:00Z","timestamp":1636070400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.bone.2021.116241","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T07:46:35Z","timestamp":1635320795000},"page":"116241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use"],"prefix":"10.1016","volume":"155","author":[{"given":"Eisuke","family":"Tsuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chie","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Karibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Hiruma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Isumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomaya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoka","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Koide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Udagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Amizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Kumakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bone.2021.116241_bb0005","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1093\/glycob\/cwm049","article-title":"Siglec-15: an immune system Siglec conserved throughout vertebrate evolution","volume":"17","author":"Angata","year":"2007","journal-title":"Glycobiology"},{"issue":"3","key":"10.1016\/j.bone.2021.116241_bb0010","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.bbrc.2011.05.015","article-title":"Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation","volume":"409","author":"Hiruma","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"21","key":"10.1016\/j.bone.2021.116241_bb0015","doi-asserted-by":"crossref","first-page":"17493","DOI":"10.1074\/jbc.M111.324194","article-title":"Siglec-15 protein regulates formation of functional osteoclasts in concert with DNAX-activating protein of 12 kDa (DAP12)","volume":"287","author":"Ishida-Kitagawa","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.bone.2021.116241_bb0020","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1002\/jbmr.1989","article-title":"Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase\/Akt and Erk pathways in association with signaling adaptor DAP12","volume":"28","author":"Kameda","year":"2013","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2021.116241_bb0025","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bone.2012.11.036","article-title":"Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice","volume":"53","author":"Hiruma","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.116241_bb0030","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.bone.2014.10.027","article-title":"Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis","volume":"71","author":"Kameda","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.116241_bb0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bone.2015.05.029","article-title":"Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) mediates periarticular bone loss, but not joint destruction, in murine antigen-induced arthritis","volume":"79","author":"Shimizu","year":"2015","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.bone.2021.116241_bb0040","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1074\/jbc.M113.494542","article-title":"Mechanism and function of monoclonal antibodies targeting Siglec-15 for therapeutic inhibition of osteoclastic bone resorption","volume":"289","author":"Stuible","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bone.2021.116241_bb0045","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bone.2018.07.026","article-title":"Siglec-15-targeting therapy increases bone mass in rats without impairing skeletal growth","volume":"116","author":"Sato","year":"2018","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.bone.2021.116241_bb0050","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","article-title":"Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment","volume":"20","author":"Prince","year":"2005","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.bone.2021.116241_bb0055","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1210\/jc.2008-2630","article-title":"Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis","volume":"94","author":"Leder","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.bone.2021.116241_bb0060","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bone.2021.116241_bb0065","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4158\/EP161435.ESGL","article-title":"American Association of Clinical Endocrinologists and American Collage of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016 executive summary","volume":"22","author":"Camacho","year":"2016","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.bone.2021.116241_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2020.115331","article-title":"Siglec-15-targeting therapy protects against glucocorticoid-induced osteoporosis of growing skeleton in juvenile rats","volume":"135","author":"Sato","year":"2020","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2021.116241_bb0075","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2220\/biomedres.32.259","article-title":"Morphological assessment of bone mineralization in tibial metaphyses of ascorbic acid-deficient ODS rats","volume":"32","author":"Hasegawa","year":"2011","journal-title":"Biomed. Res."},{"key":"10.1016\/j.bone.2021.116241_bb0080","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/oxfordjournals.jbchem.a022505","article-title":"A general method for rapid purification of soluble versions of glycosylphosphatidylinositol-anchored proteins expressed in insect cells: an application for human tissue-nonspecific alkaline phosphatase","volume":"126","author":"Oda","year":"1999","journal-title":"J. Biochem."},{"issue":"3","key":"10.1016\/j.bone.2021.116241_bb0085","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1369\/0022155418806865","article-title":"Histological effects of the combined administration of eldecalcitol and a parathyroid hormone in the metaphyseal trabeculae of ovariectomized rats","volume":"67","author":"Hasegawa","year":"2019","journal-title":"J. Histochem. Cytochem."},{"issue":"4","key":"10.1016\/j.bone.2021.116241_bb0090","doi-asserted-by":"crossref","first-page":"273S","DOI":"10.1016\/8756-3282(95)00303-U","article-title":"A histomorphometric study on effects of single and concurrent intermittent administration of human PTH (1\u201334) and bisphosphonate cimadronate on tibial metaphysis in ovariectomized rats","volume":"17","author":"Mashiba","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.bone.2021.116241_bb0095","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S8756-3282(01)00408-2","article-title":"Maintenance of vertebral body bone mass and strength created by human parathyroid hormone treatment in ovariectomized rats","volume":"28","author":"Samnegard","year":"2001","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2021.116241_bb0100","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S0022-3565(24)37566-4","article-title":"Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats","volume":"286","author":"Azuma","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.bone.2021.116241_bb0105","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1538\/expanim.55.357","article-title":"Comparative effects of alendronate and alfacalcidol on cancellous and cortical bone mass and bone mechanical properties in ovariectomized rats","volume":"55","author":"Iwamoto","year":"2006","journal-title":"Exp. Anim."},{"key":"10.1016\/j.bone.2021.116241_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR histomorphometry nomenclature committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116241_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.116095","article-title":"Anti-Siglec-15 antibody suppresses bone resorption by inhibiting osteoclast multinucleation without attenuating bone formation","volume":"152","author":"Tsukazaki","year":"2021","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2021.116241_bb0120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/glycob\/cws139","article-title":"The interaction between Siglec-15 and tumor-associated sialyl-tn antigen enhances TGF-\u03b2 secretion from monocytes\/macrophages through the DAP12-syk pathway","volume":"23","author":"Takamiya","year":"2013","journal-title":"Glycobiology"},{"issue":"4","key":"10.1016\/j.bone.2021.116241_bb0125","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/s41591-019-0374-x","article-title":"Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Nat. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2021.116241_bb0130","first-page":"107","volume":"32","author":"Dishy","year":"2017","journal-title":"J. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.bone.2021.116241_bb0135","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1042\/BST0361467","article-title":"Siglecs as positive and negative regulators of the immune system","volume":"36","author":"Crocker","year":"2008","journal-title":"Biochem. Soc. Trans."},{"issue":"9","key":"10.1016\/j.bone.2021.116241_bb0140","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of monoclonal antibodies","volume":"6","author":"Josiah","year":"2017","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"issue":"9","key":"10.1016\/j.bone.2021.116241_bb0145","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1210\/en.2011-0252","article-title":"Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats","volume":"152","author":"Li","year":"2011","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2021.116241_bb0150","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.bone.2014.07.031","article-title":"Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats","volume":"67","author":"Stolina","year":"2014","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2021.116241_bb0155","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.bone.2012.03.004","article-title":"Pharmacodynamic responses to combined treatment regimens with the calcium sensing receptor antagonist JTT-305\/MK-5442 and alendronate in osteopenic ovariectomized rats","volume":"50","author":"Fisher","year":"2012","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.bone.2021.116241_bb0160","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00223-007-9091-4","article-title":"Secreted tartrate-resistant acid phosphatase 5b is a marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model","volume":"82","author":"Rissanen","year":"2008","journal-title":"Calcif. Tissue Int."},{"issue":"1","key":"10.1016\/j.bone.2021.116241_bb0165","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1359\/jbmr.2003.18.1.134","article-title":"A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum","volume":"18","author":"Alatalo","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2021.116241_bb0170","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.bone.2014.04.033","article-title":"Effect of sequential treatments with alendronate, parathyroid hormone (1\u201334) and raloxifene on cortical bone mass and strength in ovariectomized rats","volume":"67","author":"Amugongo","year":"2014","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2021.116241_bb0175","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00198-014-2678-5","article-title":"Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass","volume":"25","author":"Amugongo","year":"2014","journal-title":"Osteoporos. Int."},{"issue":"1","key":"10.1016\/j.bone.2021.116241_bb0180","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00223-017-0255-6","article-title":"Intermittent ibandronate maintains bone mass, bone structure, and biomechanical strength of trabecular and cortical bone after discontinuation of parathyroid hormone treatment in ovariectomized rats","volume":"101","author":"Takeda","year":"2017","journal-title":"Calcif. Tissue Int."},{"issue":"3","key":"10.1016\/j.bone.2021.116241_bb0185","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00223-018-0497-y","article-title":"Sequential treatment with eldecalcitol after PTH improves bone mechanical properties of lumbar spine and femur in aged ovariectomized rats","volume":"104","author":"Sakai","year":"2019","journal-title":"Calcif. Tissue Int."},{"issue":"5","key":"10.1016\/j.bone.2021.116241_bb0190","first-page":"289","article-title":"Efficacy of switching from teriparatide to bisphosphonate or denosumab: a prospective, randomized, open-label trial","volume":"2","author":"Niimi","year":"2018","journal-title":"J. Bone Mineral Res. Plus"},{"issue":"4","key":"10.1016\/j.bone.2021.116241_bb0195","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1080\/14656566.2020.1717468","article-title":"Combination and sequential treatment in women with postmenopausal osteoporosis","volume":"21","author":"Anastasilakis","year":"2020","journal-title":"Expert. Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.bone.2021.116241_bb0200","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1084\/jem.20050645","article-title":"DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells","volume":"202","author":"Yagi","year":"2005","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.bone.2021.116241_bb0205","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.bbrc.2008.10.076","article-title":"Cell fusion in osteoclasts play a critical role in controlling bone mass and osteoblastic activity","volume":"377","author":"Iwasaki","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"33","key":"10.1016\/j.bone.2021.116241_bb0210","doi-asserted-by":"crossref","first-page":"25103","DOI":"10.1074\/jbc.R109.041087","article-title":"Cellular and molecular mechanisms of bone remodeling","volume":"285","author":"Raggatt","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.bone.2021.116241_bb0215","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrrheum.2011.181","article-title":"Epidemiology and pathogenesis of osteonecrosis of the jaw","volume":"8","author":"Reid","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"issue":"8","key":"10.1016\/j.bone.2021.116241_bb0220","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jama.2011.190","article-title":"Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women","volume":"305","author":"Park-Wyllie","year":"2011","journal-title":"JAMA"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221004075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328221004075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:58:25Z","timestamp":1757613505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328221004075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":44,"alternative-id":["S8756328221004075"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2021.116241","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2021.116241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116241"}}